Summary
This prediction ended on 22.04.15 with a price of €84,800,000. The BUY prediction by melinda for Neovacs performed very badly with a performance of -67.18%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | 1.917% | 1.088% | 17.187% | 65.270% |
| iShares Nasdaq 100 | 0.911% | 1.674% | 7.930% | 101.983% |
| iShares Nikkei 225® | 0.833% | -1.712% | 12.100% | 44.368% |
| iShares S&P 500 | 0.242% | 1.258% | 3.167% | 62.336% |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Biotech-
Markt Antikörper
(Laufzeit überschritten)